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Abstract
Background: Recurrent or metastatic lung cancer is difficult to manage. This retrospective study aimed to assess
the efficacy of repeated iodine-125 seed implantations combined with external beam radiotherapy (EBRT) for locally
recurrent or metastatic stage-III/IV non-small cell lung cancer (NSCLC).
Methods: Eighteen previously treated stage-III/IV NSCLC patients with local or metastatic recurrences underwent 1-
to-3 iodine-125 implantations. Six of these patients received palliative EBRT and six patients received combined
chemotherapy using gemcitabine and cisplatin. Near-term treatment efficacy was evaluated 3 months after seed
implantation by comparing changes in tumor size on computed tomography images; the evaluated outcomes
were complete response, partial response, stable disease, and local tumor control rate. Long-term efficacy was
assessed based on 1- and 2-year survival rates.
Results: Patients were followed up for 6 to 50 months. The overall (i.e., complete + partial) response rate was 87.
4 %. The local control rates after the first, second, and third years were 94.1, 58.8 and 41.2 %, respectively.
Conclusions: The results of this study demonstrated that repeated implantation of radioactive particles combined
with EBRT is a safe treatment that effectively controlled local recurrence and metastasis of stage III/IV NSCLC.
Keywords: Non-small cell lung cancer, I125 seed implantation, External beam radiotherapy, Metastasis, Recurrence,
Brachytherapy
Introduction
Lung cancer is the leading cause of cancer death in
both men and women worldwide, and its prevalence
is increasing [1]. Conventional treatment for lung
cancer includes palliative radiotherapy and chemo-
therapy, which has shown limited potential in in-
creasing long-term survival rates [2]. Using external
beam radiotherapy (EBRT) alone, it is difficult to
deliver a sufficient radiation dose to patients with
large or advanced tumors, in order to avoid damage
to adjacent normal tissues [3]. Repeated EBRT has
limited efficacy for these patients and is associated
with increased side effects because of the low toler-
ance of the surrounding normal tissue [4]. Further-
more, because a large proportion of lung cancers are
diagnosed at an advanced stage, the main challenges
to treatment are recurrence and metastasis, which is
difficult to manage. Extensive resection of a locally
recurrent lung cancer is associated with high recur-
rence risk and significant mortality. Mediastinal me-
tastasis and metastasis in the brain, bone, or distant
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organs are common in patients with advanced lung
cancer [5]. Controlling the size of these metastatic
tumors may help to improve long-term survival rate.
Radioactive seed implantation, which is a form of
brachytherapy, can be performed repeatedly. It has been
successfully applied for treating inoperable solitary lung
cancers, while avoiding excessive radiation exposure to
surrounding tissues [6–8]. Clinically, brachytherapy
using iodine-125 seed implantation is capable of deliver-
ing a sufficient dose of radiation to the tumor mass.
However, in many recurrent and metastatic lung can-
cers, important organs, large vessels, or bone structures
often block the pathway to the lesions, making these tu-
mors inaccessible to needle puncture, and leading to an
unsatisfactory distribution of the implanted iodine-125
seeds [9, 10]. In addition, brachytherapy would become
very risky when conducting implantation in metastatic
lymph nodes located near the mediastinal macrovascular
area.
In this retrospective study, we investigated the effi-
cacy of combining iodine-125 seed implantations
with EBRT for salvage treatment of advanced lung
cancers. Eighteen recurrent advanced non-small cell
lung cancer (NSCLC) patients who previously under-
went iodine-125 seed implantations received com-
puted tomography (CT)-guided iodine-125 seed
reimplantations in combination with EBRT.
Materials and methods
Patients
The Institutional Review Board and Ethics Committee of
General Hospital of Chengdu Military Region of the
PLA (#08-00125) approved this study. All patients pro-
vided written informed consent.
Between October 2006 and September 2014, 18 patients
with recurrent or metastatic stage III/IV NSCLC (Table 1)
underwent CT-guided iodine-125 seed reimplantations,
with or without EBRT, at the General Hospital of Chengdu
Military Region of PLA. All of the 18 patients enrolled in
this study had a history of iodine-125 seed implantations
and met the following criteria: NSCLC was confirmed by
histopathological examination; a CT scan indicated a solid
mass or nodule in the lung area, or nearby the mediasti-
num; local recurrence or restricted metastasis at <3 re-
gions; the Karnofsky Performance Status score was ≥60.
Treatment
Among the 18 patients evaluated (Tables 1 and 2),
two patients with vertebral metastasis (Patients 8 and
17) and great pain and one patient with metastasis in
the lymph nodes of the mediastinum (Patient 13) re-
ceived palliative EBRT at 20–30 Gy. In addition, three
patients with mediastinum metastasis (Patients 5, 10,
and 18) received palliative EBRT at the lymph nodes
of the mediastinum. Two patients with brain
Table 1 Clinical features of the present 18-patient cohort
No. Age, y Gender TNM KPS a Tumors Size, cm3 Seeds b; activity, mCi MPD, Gy
1 72 M T3N1M0 70 L, lung SCC 6 × 5 × 5 72/59/43; 0.7–0.8 130
2 57 F T3N1M0 80 R, lower lung adenocarcinoma 6 × 6 × 5 76/45/52; 0.8 140
3 59 M T3N1M1 70 L, lower lung adenocarcinoma 6 × 5 × 4 77/20; 0.7 140
4 59 M T3N2M0 70 L, lung SCC 5 × 5 × 4 66/62; 0.8 150
5 73 M T2N2M0 80 R, lower lung adenocarcinoma with mediastinal LNM 6 × 7 × 6 63/24; 0.8 140
6 70 M T3N1M1 70 L, lung SCC with brain metastases 5 × 5 × 4 45; 0.7 130
7 54 M T3N1M0 60 L, lung poorly differentiated SCC 8 × 7 × 5 100/40; 0.6 150
8 81 M T3N1M0 70 R, lower lung adenocarcinoma with vertebral metastases 6 × 5 × 5 65/45; 0.8 140
9 66 F T4N1M0 80 R, lower lung SCC 6 × 5 × 4 70/62; 0.7 130
10 67 M T2N1M1 70 R, upper lung SCC with LNM 4 × 4 × 3 48/20/14; 0.8 130
11 73 M T2N1M0 60 L, lung SCC in situ recurrence after 1 y 5 × 5 × 4 62/40; 0.8 140
12 78 F T2N0M0 70 R, upper lung squamous 3 × 1 × 2 23/40; 0.7 140
13 65 F T4N2M0 70 SCC with mediastinal lymph node metastases 7 × 6 × 6 89; 0.7 130
14 75 M T3N1M0 60 Adenocarcinoma 5 × 6 × 5 19/40; 0.7 130
15 66 M T3N2M1 80 R, upper lung adenocarcinoma with vertebral metastases 7 × 5 × 4 78; 0.6 160
16 60 F T2N1M1 70 R, upper lung adenocarcinoma with adrenal metastasis 6 × 5 × 5 70; 0.8 140
17 57 M T4N1M1 75 L, lung SCC associated with vertebral metastases 5 × 5 × 3 41/36; 0.8 130
18 64 M T3N2M0 80 R, lung moderately differentiated SCC with mediastinal LNM 4 × 5 × 5 52; 0.8 120
L left, LR local recurrence, LNM lymph node metastasis, MPD matched peripheral dose, R right, SCC squamous cell carcinoma, TNM tumor, node, metastasis stage
a KPS score; b number of iodine-125 seeds per implantation
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metastasis (Patients 3 and 6) underwent gamma knife
radiosurgery.
Seven patients (Patients 2, 5, 7, 11, 14, 16, and 18) re-
ceived combined chemotherapy using gemcitabine and
cisplatin. The regimen had a 21-day schedule during
which gemcitabine (1000 mg/m2) was administered on
the first and eighth days, and cisplatin (20 mg/m2) on
the first, second, and third days. The chemotherapy
schedule was repeated for 4 to 6 cycles, if tolerated.
All patients received iodine-125 implantations. One-
to-2 weeks before iodine-125 seed implantation, routine
blood examination, bleeding time, and coagulation tests
were performed to exclude contraindications for needle
puncture.
Routine enhanced-CT scans were also performed for
assessing tumor volume. Briefly, gross tumor volume
was outlined and used as the planning target volume.
The minimum matched peripheral dose was set at 110–
140 Gy. All the implantations were performed in a
standard CT room under local anesthesia, and guided by
CT using a Fudan TPS 2.00 brachytherapy planning
system [11] (Table 1). Iodine-125 seeds with a nominal
activity of 0.5–0.7 millicurie (mCi) per seed and a diam-
eter <1 mm were implanted using a turntable implant-
ation gun with 18-G implantation needles (XinKe
Pharmaceutical, Shanghai, China), while avoiding punc-
turing of the nearby vessels and other organs. Patients
were kept in the radiation oncology/interventional ward
for 1-to-2 days after implantation.
The distribution of the radioactive seeds was evaluated
immediately after implantation by CT scans. Re-
implantation was conducted for sites showing an uneven
distribution of seeds. The minimum peripheral dose was
110–140 Gy (mean, 120 Gy).
Follow-up and efficacy evaluation
Each patient underwent a follow-up examination at 1
and 3 months after the seed implantation, and then
every 3 months for up to 60 months. Physical examina-
tions, blood tests, and thoracic CT scans were per-
formed. Patients’ pain score, the rate of radiation
pneumonia, time to recurrence, survival and local con-
trol rates, and median survival times were recorded. Sur-
vival and locoregional metastasis rates were calculated
using the Kaplan-Meier method. For calculation of the
survival rate, deaths from any cause were scored as
events. Local control was defined as lack of tumor pro-
gression in areas adjacent to or at the site of iodine-125
seed implantation and adjacent regions.
To evaluate near-term efficacy after brachytherapy, all
patients underwent CT scans 3 months after seed im-
plantation. The total volume of each tumor was normal-
ized to that before implantation. Complete response was
defined as the complete disappearance of a lesion for
>4 weeks. A partial response was considered when the
size of the lesion decreased by >50 %, and then remained
unchanged for 4 weeks. Stable disease was defined when
the size of the tumor decreased by <50 % or increased
Table 2 Recurrence and survival of the present 18-patient cohort
No. Age, y Gender Recurrence/metastasis after first seed implant, further treatment TTR mo Survival, mo
1 72 M LR; 3 implants 11/12 43
2 57 F LR; 3 implants 10/13 31
3 59 M Brain metastases; whole brain irradiation + 2 implants 24 Living
4 59 M Adrenal metastasis (R); 2 implants 13 Living
5 73 M LR; 2 implants, yet failed due to hemoptysis 15 15
6 70 M — 12 Living
7 54 M LR; 2 implants + mediastinal external irradiation 11 13
8 81 M — 14 24
9 66 F LR; 2 implants 17 Living
10 67 M Neck metastasis; 3 implants 11/13 17
11 73 M LR; 2 implants 14 Living
12 78 F L; lung metastases at 6 years after first treatment; 2 implants 78 Living
13 65 F — 0 Living
14 75 M Neck metastasis; 2 implants 13 16
15 66 M — 16 21
16 60 F Neck metastasis; 1 implant + adrenal EBRT 0 11
17 57 M — 0 12
18 64 M — 0 Living
LR local recurrence, TTR time to recurrence
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by <25 %. Response rate was defined as the sum of the
complete response and partial response. Local tumor
control was defined as the absence of tumor progression
detected by CT (i.e., stable disease + partial response +
complete response). Long-term efficacy was assessed ac-
cording to 1-year and 2-year survival rates.
Results
Efficacy
Eighteen patients with recurrent and metastatic advanced
NSCLC received a total of 35 implantations of iodine-125
seeds (Table 1). Based on the imaging results obtained at
approximately 2 months after the first implantation, near-
term complete response was achieved in seven cases, par-
tial response in another six cases, and stable disease in five
cases. The overall response rate was 72.22 % (i.e., 13/18).
During follow-up after the first round of iodine-125 seed
implantation, 12 of the 18 patients experienced tumor re-
currence and underwent a second round of iodine-125
seed implantations (Table 2). Four of these 13 patients
(Nos. 1, 2, 3, and 10) experienced tumor recurrence again,
and underwent a third round of seed implantations. Meta-
static tumors were found in the adrenal glands of patient
No. 16, and in the vertebra of patient Nos. 8 and 10.
For patient Nos. 6, 8, 13, 15, 17 and 18, the residual
tissues within each tumor mass showed no enhancement
on the CT or positron emission tomography (PET)-CT
images obtained 3 months after the first round of
iodine-125 seed implantation (Table 2). In eight patients,
PET-CT scans detected reduced metabolic activity in the
lesions or disappearance of the lesions and residual tis-
sues within the tumor mass.
Fig. 1 Kaplan-Meier curve of 18 patients with recurrent or metastatic
stage III/IV non-small cell lung cancer
Fig. 2 CT images of moderately differentiated squamous cell carcinoma (4 × 5 × 5 cm3) in the lower right lung (a) with metastasis in the lymph
nodes of the mediastinum (b) in a 64-year old man (No. 18). The patient received iodine-125 seed implantation for lung tumor (c) and external
beam radiotherapy for lymph node metastasis (d). Complete disappearance of the lung tumor (e) and lymph node metastasis (f) was observed
1 month after treatment
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As calculated from the Kaplan-Meier Curve (Fig. 1),
the median survival time for this 18-patient cohort was
31 months, and the progression-free survival time was
6–8 months. The overall 1-year and 2-year survival rates
were 62.5 and 32.7 %, respectively.
Ten patients reported cancer-related pain before treat-
ment. After treatment, complete relief was achieved in all
patients with mild pain (n = 4), and in two of four patients
with moderate pain. Partial relief was achieved in the
other two of the four patients with moderate pain, and in
one of two patients with severe pain. One patient with se-
vere pain showed no relief. The three patients with partial
or no pain relief received steroid-based painkillers.
Two patients (Nos. 7 and 14) experienced rapid tumor
recurrence and metastasis in multiple sites after the second
implantation, and died of multiple organ failure thereafter.
Adverse reactions and complications
Complications include pneumothorax and hemoptysis,
both are common to puncture. One patient had severe
hemoptysis.
The most common complications reported were pain,
pneumothorax, and hemoptysis, which are common to
puncture. One patient developed grade 2 or higher radi-
ation pneumonitis after the first round of iodine-125
seed implantation. Three patients experienced pneu-
monitis after the second round of iodine-125 seed im-
plantation. One patient (No. 5) with squamous cell lung
carcinoma in the lower right lung experienced tumor re-
currence 18 months after the first round of seed im-
plantation. During the puncture process of the second
round of seed implantation, the patient developed severe
hemoptysis and died of respiratory failure 3 days later.
All the other patients underwent no radiation pneumon-
itis or other serious complications after the second
round of iodine-125 seed implantation.
Typical cases
A 64-year old man (No. 18) with moderately differenti-
ated squamous cell carcinoma (4 × 5 × 5 cm3) in the
lower right lung and metastasis in the lymph nodes of
the mediastinum showed complete response to the com-
bined therapy (Fig. 2). Iodine-125 seeds were implanted
to his lung tumor region for brachytherapy; EBRT was
used to treat lymph node metastasis. The patient showed
complete disappearance of the lung tumor, 2 months
Fig. 3 CT images of a squamous cell lung carcinoma in the lower left lung in a 56-year-old man (No. 3) with brain metastasis: (a) before treatment;
(b) 12 months after the first iodine-125 seed implantation of iodine-125 seeds; (c) 30 months after the first implantation showing a recurrent tumor
mass (8 × 4 cm2) in the lower left thoracic cavity; (d) 33 months after the first, i.e. 3 months after the second implantation, showing that the tumor size
had decreased by 50 %; (e) during the third implantation, i.e., 42 months after the first implantation, showing metastasis on the right side of the chest
wall; (f) Immediately after the third implantation
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after implantation. He developed no radiation pneumo-
nia. He was tumor-free for 2 years and is still living.
A 56-year-old man (No. 3) with squamous cell lung
carcinoma in the lower left lung and brain metastasis ex-
hibited a significant reduction in tumor size after the
first implantation of iodine-125 seeds (Fig. 3). Brain
EBRT effectively provided control of the metastasis,
while the patient also received 6 cycles of chemotherapy.
Tumor size gradually reduced during follow-up and the
CT image was tumor-free at the 12-month follow-up.
Thirty months after the first round of brachytherapy, a
recurrent tumor mass (8 × 4 cm2) was detected in the
lower left thoracic cavity and the patient underwent a
second seed implantation procedure. Three months later,
the tumor size was reduced by 50 %. Forty-two months
after the first brachytherapy, metastasis was found on
the right side of the chest wall, and the patient received
seed implantation for the third time and lived for
4 months afterwards.
A 65-year-old woman (No. 13) had squamous cell lung
carcinoma in the upper left lung (7 × 5 cm2) and metasta-
sis in the superior border of the pericardium and mediasti-
num (3 × 4 cm2) (Fig. 4). Due to the large volume of the
tumor in the upper left lung, it was hard to keep the
volume of normal lung tissue that receiving a radiation
dose of 20 Gy (V20) under 30 % when conducting EBRT.
Moreover, it was risky to conduct a puncture of the tumor
in the mediastinum due to its proximity to large blood
vessels. Therefore, seed particles were implanted in the
lung tumor while EBRT was delivered to the mediastinum
tumor at a dose of 30 Gy. One year after implantation,
complete response was achieved. Three years after im-
plantation, no recurrence was observed.
A 57-year-old man (No. 17) had an adenocarcinoma
cell lung carcinoma in the lower right lung (3 × 2 cm2)
and metastasis in the vertebra (Fig. 5). Iodine-125 seeds
were implanted in both regions and the patient sur-
vived for 15 months without further metastasis in the
vertebra.
Discussion
Stage III/IV NSCLC patients with recurrence and metas-
tasis are often inoperable. Palliative radiotherapy and
chemotherapy are recommended for these patients, but
the efficacy of EBRT and chemotherapy is very limited
and the survival time is often short (e.g., 6–9 months).
In the present study, EBRT was combined with iodine-
125 seed implantations for treating locally recurrent
fig. 4 PET-CT image of a massive squamous cell carcinoma (7 × 5 cm2) in the upper left lung with metastasis in the superior border of the
pericardium and mediastinum (3 × 4 cm2) in a 65-year-old woman (No. 13) (a). The metastasis region was treated with EBRT at a dose of 30 Gy
(b) and the massive lung cancer region was implanted with iodine-125 seeds (red and purple dots) for brachytherapy (c) guided by CT. Thoracic
CT image was tumor-free at 1-year follow-up (d), and showed no recurrence of cancer at 3-year follow-up (e)
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NSCLC with concurrent metastasis (patient Nos. 6, 13,
15, 17 and 18). The iodine-125 seed implantations were
delivered, at enough radiation doses, to tumors that were
difficult to reach by EBRT. We found that repeated
iodine-125 seed implantations were beneficial for pa-
tients with multiple recurrences, leading to longer me-
dian survival time and progression-free survival time,
and higher overall 1-year and 2-year survival rates.
For tumors >5 cm, it is difficult to deliver a large
enough dose with EBRT in order to avoid damaging ad-
jacent normal tissues such as the lung, spinal cord, and
heart [12]. It has been reported that the effective EBRT
dose for tumors >5 cm is greater than 100 Gy [3]. How-
ever, this high dose of EBRT can lead to an increase in
V20 (i.e., more than 30 % of the surrounding normal
lung tissue receiving a radiation dose of 20 Gy), thereby
increasing the risk of complications. Thus, low doses of
EBRT (30–40 Gy) are typically delivered for palliative
treatments. In contrast, iodine-125 seed implantation
has the potential to deliver a higher radiation dose to a
tumor mass (100–140 Gy), and this dose drops off
sharply within a short distance. Consequently, adjacent
normal tissues are exposed to a minimal dose of
radiation, and the short-term risk for serious radiation-
induced pneumonitis is reduced [3]. In addition, com-
pared with EBRT, the delivered dose to a tumor by
iodine-125 seed implantation can be as much as 2-fold
higher [13], with superior treatment efficacy [14]. The
response rate reported for EBRT for advanced lung can-
cer is low, usually below 60 % [14]. In the present study,
the response rate for iodine-125 seed implantation was
88 %, consistent with the rates reported in previous
studies [6, 15].
There are limitations associated with iodine-125 seed
implantation. First, it is difficult to perform needle punc-
ture for a metastasis close to the mediastinum, and this
may result in an unsatisfactory distribution of iodine-
125 seeds. Similarly, needle punctures of metastases in
the brain or in the lymph nodes of the mediastinum are
problematic because of to their proximity to large blood
vessels, the heart, or bone structures. The efficacy of
iodine-125 seed implantations can also be limited by
many factors, such as shielding by bone structures,
differences in brachytherapy planning systems, and
Fig. 5 CT images showing brachytherapy of non-small cell lung adenocarcinoma (3 × 2 cm2) with vertebral metastasis in a 57-year-old man (No.
17). Both the adenocarcinoma region in the lower right lung (a) and the vertebral metastasis region (c, d) were implanted with iodine-125 seeds.
One-year follow-up images showed good tumor control in both regions (b, e)
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individual differences. Generally, iodine-125 seed im-
plantation is an effective treatment for large tumors.
However, its efficacy for poorly differentiated tumors
such as small cell lung cancer is poor, due to the low ini-
tial dose of iodine-125 that is applied. Thus, protactinium-
103, which has a higher initial dose, may be more effective
for poorly differentiated tumors such as small cell lung
cancer.
Iodine-125 seed implantation in combination with
EBRT appears to control recurrent lung cancer and me-
tastasis effectively. For example, the progression-free
survival time for the present cohort was 6–8 months,
the 1 and 2-year survival rates were 62.5 and 32.7 %, and
middle survival time of 18 patients was 31 months, re-
spectively. Moreover, these results are an improvement
over that have been previously reported [16, 17]. One
reason for this may be because the combined iodine-125
seed implantation and EBRT provide a better control of
the late-stage recurrent lung cancers and metastases in
vital organs by increasing the cumulative radiation dose.
Another reason may be because that all of in the present
study the patients included only experienced restricted
metastasis, and patients with diffusive or multiple metas-
tasis were excluded.
Conclusions
The results of this study demonstrated that iodine-125
seed implantation in combination with EBRT has the
potential to effectively control recurrent and metastatic
lung cancer, with less invasiveness, fewer side effects,
and higher survival rates. For tumors that are in proxim-
ity of the mediastinum or large blood vessels, and thus
are inaccessible to puncture, additional EBRT was also
beneficial. Thus, iodine-125 seed implantation in com-
bination with EBRT should be considered an alternative
therapy for advanced-stage NSCLC patients. Further
studies are needed to confirm this treatment.
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